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ARTICLE
Joint Belgian recommendation on screening for DPD-deficiency in patients 
treated with 5-FU, capecitabine (and tegafur)
Veerle Casneufa, Ivan Borbathb, Marc Van den Eyndec, Yolanda Verheezend, Wim Demeye, Alain G Verstraetef, 
Kathleen Bm Claesg, Vincent Haufroidh* and Karen P Geboesi*
aDepartment of Gastroenterology, OLV Aalst, Aalst, Belgium; bDepartment of Hepatology and Gastroenterology, University Hospital St 
Luc/UCLouvain, Woluwe; cDepartment of Oncology, University Hospital St Luc/UCLouvain, Woluwe; dDepartment of Oncology, Jessa 
Ziekenhuis, Hasselt; eDepartment of Oncology, AZ Klina, Brasschaat Belgium; fDepartment of Clinical Biology, UZ Gent, Gent; gDepartment 
of Medical Genetics, UZ Gent, Gent; hDepartment of Toxicology and Applied Pharmacology, University Hospital St Luc/UCLouvain, 
Woluwe; iDepartment of Gastroenterology, UZ Gent, Gent
ABSTRACT
Objectives: Fluoropyrimidines such as 5-Fluorouracil (5-FU), capecitabine and tegafur are 
drugs that are often used in the treatment of maliginancies. The enzyme dihydropyrimidine 
dehydrogenase (DPD) is the first and rate limiting enzyme of 5-FU catabolism. Genetic varia-
tions within the DPYD gene (encoding for DPD protein) can lead to reduced or absent DPD 
activity. Treatment of DPD deficient patients with fluoropyrimidines can result in severe and, 
rarely, fatal toxicity. Screening for DPD deficiency should be implemented in practice.
Methods: The available methods in routine to screen for DPD deficiency were analyzed and 
discussed in several group meetings involving members of the oncological, genetic and 
toxicological societies in Belgium: targeted genotyping based on the detection of 4 DPYD 
variants and phenotyping, through the measurement of uracil and dihydrouracil/uracil ratio in 
plasma samples.
Results: The main advantage of targeted genotyping is the existence of prospectively vali-
dated genotype-based dosing guidelines. The main limitations of this approach are the 
relatively low sensitivity to detect total and partial DPD deficiency and the fact that this 
approach has only been validated in Caucasians so far. Phenotyping has a better sensitivity 
to detect total and partial DPD deficiency when performed in the correct analytical conditions 
and is not dependent on the ethnic origin of the patient.
Conclusion: In Belgium, we recommend phenotype or targeted genotype testing for DPD 
deficiency before starting 5-FU, capecitabine or tegafur. We strongly suggest a stepwise 
approach using phenotype testing upfront because of the higher sensitivity and the lower 
cost to society.
Background on the use of 5-Fluorouracil and 
toxicity
Fluoropyrimidines such as 5-Fluorouracil (5-FU), cape-
citabine and tegafur, are pyrimidine analogues, anti-
neoplastic agents which act as an antimetabolite to 
uracil. 5-FU is administered intravenously and capeci-
tabine and tegafur are oral prodrugs.
5-FU inhibits activity of thymidilate synthase and thus 
deoxythymidine monophosphate synthesis through 
complex formation. This results in phase-specific DNA- 
synthesis inhibition. Deoxy-fluoronucleosides inhibit de 
novo synthesis of pyrimidine nucleotides.
By the above-mentioned mechanisms, 5-FU inter-
feres with cell division and growth, acting mainly on 
tissues with rapid cell division, such as bone marrow, 
epithelium of the gastrointestinal tract and oral mucosa.
5-FU and capecitabine are indicated mainly for the 
treatment of gastrointestinal malignancies (gastric, 
colon, pancreatic, oesophageal, rectal cancer, cholan-
giocarcinoma), head and neck cancer and breast can-
cer. Tegafur, not frequently used in Belgium, is 
administered orally (with gimeracil and oteracil) for 
gastric cancer, combined with cisplatinum.
Indications for treatment vary over time. For 
instance: the use of FEC (5-FU, epirubicine, cyclofosfa-
mide) in breast cancer has decreased over time, but 
FOLFIRINOX (5-FU, irinotecan and oxaliplatin) is pre-
scribed extensively in pancreatic cancer, a tumor that is 
rising in incidence. There are regional differences in 
availability of certain drugs because of regulatory or 
financial reasons.
Only a small fraction of 5FU or capecitabine is trans-
formed into active cytotoxic metabolites. More than 
80% of the administered dose is detoxified and 
excreted as metabolites (mainly fluoro-beta-alanine, 
FBAL) in urine.
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The DPYD gene encodes for the synthesis of an 
enzyme called dihydropyrimidine dehydrogenase 
(DPD), involved in the breakdown of uracil and thy-
mine when they are not needed. DPD is the first and 
rate limiting enzyme of 5-FU catabolism, and has 
a pivotal role in 5-FU and prodrugs elimination pat-
terns. Deficiency of this enzyme leads to the drug 
buildup that causes fluoropyrimidine toxicity. Genetic 
variations within the DPYD gene (encoding for DPD 
protein) can lead to reduced or absent DPD activity 
and individuals who are heterozygous or homozygous/ 
compound heterozygous for these variations may have 
partial or complete DPD deficiency. Treatment of DPD 
deficient patients with fluoropyrimidines can therefore 
result in severe and, rarely, fatal toxicity.
The first case of a fatal outcome caused by DPD 
deficiency has already been published in 1985. Drug 
labels include a safety warning for DPD deficiency and 
EMA and FDA as well as oncological societies recom-
mend not to use 5-FU and its prodrugs in case of total 
DPD deficiency. In these cases, toxicity appears early 
on, in the first treatment cycle. An antidote, uridine 
triacetate (Vistogard®), exists but is very difficult to 
obtain in Europe and should be administered within 
96 hours after administration of 5-FU.
Epidemiology of DPD deficiency
In the Caucasian population, approximately up to 8% 
has a partial DPD deficiency and up to 0.5% is fully DPD 
deficient [1–4]. Not all toxicities experienced during 
treatment with 5FU can be attributed to DPD defi-
ciency. In the literature, it is reported that about 50% 
of overall 5-FU related toxicities could be attributed to 
diminished DPD activity [1–3].
In France, among 100 000 patients exposed to cape-
citabine or 5-FU yearly, nearly 8000 patients would 
have a partial DPD deficiency and up to 500 would 
be fully DPD deficient.
In Belgium, with 17 000 new patients potentially 
exposed to capecitabine or 5FU yearly, this would 
amount to 1300 patients with a partial DPD deficiency 
and up to 85 fully DPD deficient.
Several questions need to be addressed. What would 
be the best strategy to identify patients with total or 
partial DPD deficiency? What is the performance of 
available tests? How would we implement the tests in 
daily practice? How would we ensure an adequate turn- 
around-time (TAT), which should be kept within 7, max 
14 days? And finally, what would be the cost?
Available screening tests [5]
Currently, two methods are available in routine to 
screen for DPD deficiency:
● The genotyping approach, based on the detec-
tion of four DPYD variants known to be associated 
with decreased DPD activity (*2A, *13, p.D949V 
and HapB3). This approach is also known as ‘tar-
geted DPYD genotyping’ and is performed on 
DNA extracted from EDTA blood.
● The phenotyping approach, or the estimation of the 
DPD activity, through the measurement of uracil (U) 
and dihydrouracil/uracil ratio (UH2/U) in plasma.
Genotyping
A recent update Table 1 from the Clinical 
Pharmacogenetics Implementation Consortium 
(CPIC) now recommends to search for at least 4 
DPYD variants associated with either a total loss 
(DPYD*2A, rs3918290, c.1905 + 1 G > A and 
DPYD*13, rs55886062, c.1679 T > G) or a reduced 
function (rs67376798, c.2846A>T, p.Asp949Val and 
HaplotypeB3, rs75017182, c.1129–5923 C > G/ 
rs56038477, c.1236 G > A, p.E412E/rs56276561, 
c.483 + 18 G > A) of the DPD enzyme [4].
However, not all toxicity related to DPD deficiency 
can be explained by these four variants in the DPYD 
gene. For instance, in one study, complete DPYD 
sequencing in a subgroup with low enzyme activity 
and without DPYD*2A variant revealed 10 genetic var-
iants, of which 4 had not been described previously [6]. 
Presence of other variants in regions of the DPYD gene 
that have not been sequenced and genetic variants in 
other (i.e., modifier) gene regions (e.g., miR27a and 
miR27b) that determine DPD enzyme activity might 
be the reason that we cannot explain all cases of 
a decreased enzyme activity even with full DPYD 
sequencing. In addition, other (e.g., environmental) 
factors determine part of DPD enzyme activity. 
Furthermore, it is not unlikely that comedication can 
influence the expression of the DPD enzyme. Also, 
Table 1. Most frequent alleles found, based on a presentation of V haufroid, BGDO april 2019.





*2A rs3918290a c.1905 + 1 G > A N/A No function 0 14
*5 rs1801159 c.1627A>G p.I543V Normal 1 14
*9A rs1801265 c.85 T > C p.C29R Normal 1 15
*13 rs55886062 c.1679 T > G p.I560S No function 0 14
rs67376798 c.2846A>T p.D949V Decreased 0,5 16
HapB3 rs75017182, rs56038477, 
rs56276561
c.1129–5923 C > G, c.1236 G > A, 
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a high variability of DPD activity for a same variant has 
been demonstrated [6]. The sensitivity of targeted 
DPYD genotyping is 25%, the specificity is 95% [4,7,8].
Dosing recommendations published for capecita-
bine and 5-FU are based on a scoring system where 
alleles with a total loss of activity are attributed a score 
of 0, alleles with reduced activity a score of 0.5 and 
alleles with normal activity a score of 1. Then, the 
activity score for the genotype is calculated as the 
sum of the scores obtained from maternal and paternal 
alleles and a normal individual will have a score of 2.
In terms of dosing recommendations, for an activity 
score of 1.5, it was initially recommended to reduce the 
dose by 25% to 50%, for an activity score of 1, to 
reduce the dose by 50% and for activity scores of 0.5 
and 0, to avoid – when possible – treatment using 5-FU 
or capecitabine [4]. These dosing guidelines recom-
mended by the CPIC have been tested in 
a prospective pharmacogenomics (PGx) study at the 
end of 2018 [7]. Briefly, the authors showed that a 50% 
dose reduction in DPYD*2A and DPYD*13 heterozy-
gous patients was adequate in terms of drug safety 
while a larger dose reduction of 50% (instead of 25%) 
would probably also be necessary in c.2846A>T and 
c.1236 G > A (HapB3) carriers. They concluded that 
prospective DPYD targeted genotyping was feasible 
and cost-efficient in routine clinical practice and that 
implementation of DPYD genotype-guided individua-
lized dosing should be a new standard of care [8] 
Figure 1.
In summary, the main advantages of the targeted 
genotyping approach are (i) its simplicity of imple-
mentation in terms of pre-analytical and analytical 
conditions and (ii) the existence of prospectively 
validated genotype-based dosing guidelines. 
However, the main limitations of this approach are 
(i) the quite low sensitivity to detect total (and par-
tial) DPD deficiency and (ii) the fact that this 
approach has only been validated in Caucasians so 
far [1–4].
Phenotyping
To overcome the main limitations of the targeted 
genotyping test, a phenotyping approach based on 
the measurement of U and UH2 in plasma before 
treatment has been proposed. Plasma concentra-
tions of U and UH2 are commonly measured by high 
BGDO recommendaon DPD-deficiency screening 
Genotyping and Dose Adaptations: 
- CPIC made a proposal for calculation of the gene activity based on the detection of the 
4 principal variants, i.e. DPYD*2A, DPYD*13, c.2846A>T and HapB3 (7): 
o DPYD*2A and DPYD*13 alleles lead to a NON functional enzyme (Activity 
score 0): in case of homozygous patients, there is a contra-indication for 
administration of 5-FU and capecitabine. 
o It was originally suggested that DPYD c.2846A>T and HapB3 have a reduced 
DPD activity of 50% (Activity score 0.5), but recent insights suggest an even 
lower activity and score (Activity score 0) . 
o Normal alleles (absence of any of the 4 variants) have a normal DPD activity 
(Activity score 1). 
Activity should be counted for each allele and summed 
If genotype score 2, normal dose 
If genotype score 1,5 or 1, 50% of the dose 
If genotype score 0,5 or 0, contraindication 
At the second cycle, the doses should be reconsidered depending on the tolerance of the 
treatment and discussion with the pharmacist if possible. 
Figure 1. Genotyping and dose adaptations.
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performance liquid chromatography (HPLC) with dif-
ferent possible detection methods (UV spectrophoto-
metry, mass spectrometry). Nowadays, most of the 
methods are based on highly sensitive and specific 
tandem mass spectrometry (LC-MS/MS) technology 
and results can be compared between laboratories 
because external quality control programs are avail-
able. High specificity, but more importantly, high 
sensitivity has been proven when performed in cor-
rect analytical conditions [1,2,9]. Three prospective 
observational studies assessed the performance of 
DPD phenotyping [9–11]. The original study was con-
ducted in 252 colorectal cancers treated with intrave-
nous 5-FU. The authors reported fairly similar results 
between UH2/U and plasma U regarding grade 3–4 
toxicity (sensitivity = 82% and 88%; specificity = 78% 
and 69%, respectively). This study showed that the 
clearance of 5-FU was significantly correlated with 
U plasma concentration (inverse correlation) whereas 
it was not correlated with the UH2/U ratio [9]. The two 
other studies concluded that U was more effective 
than UH2/U in predicting the toxicity of capecitabine 
[10,11]
Both UH2/U ratio and U are continuous variables. 
Interpretation thus requires the determination and the 
validation of threshold values to distinguish patients 
with DPD deficiency from non-deficient patients. The 
literature available regarding UH2/U threshold is 
scarce and suggests large heterogeneity between 
laboratories. This is primarily due to the variability in 
the analytical methods used at that time (HPLC with 
UV detection, diode array or MS-MS) and to analytical 
interference in UH2 determination using non-LC-MS 
/MS methods. In contrast, the three independent pro-
spective studies previously cited converge remarkably 
on the threshold value of U determining a risk of 
toxicity: greater than 15 ng/mL for the historical 
study and 16 ng/mL for the other two, leading to 
a general consensus for a cut-off at 14 ng/mL [9–12]. 
It is commonly admitted that U > 100 ng/mL is asso-
ciated with DPD total deficiency (although this could 
not be validated prospectively, given the rarity of this 
phenotype) [2,9–12] Figure 2.
In summary, the main advantages of the pheno-
typing approach are (i) a better sensitivity, com-
pared with the genotyping approach, to detect 
total and partial DPD deficiency and (ii) its interpre-
tation which is not dependent of the ethnic origin of 
the patient. However, it must be stressed that the 
main limitation of the phenotyping test is the very 
strict pre-analytical requirements. Indeed, U level 
rapidly increases in whole blood mainly when the 
sample is kept at room temperature and the max-
imum delay for centrifugation and plasma freezing is 
1h30 after blood collection. Furthermore, pheno-
type-based dosing recommendations still need to 
be validated in prospective trials.
Other tests
Full DPYD sequencing can be used in order to 
detect all variants. This test cannot be considered 
a routine test yet because several variants are still 
of unknown significance. However; in case of 
absence of correlation between phenotype and tar-
geted genotype, it would be important to screen for 
other variants in order to improve our knowledge 
and improve clinical decisions in the future. 
Complementation of full DPYD sequencing with 
phenotyping may lead to more adequate interpre-
tation of variants of unknown clinical significance. 
Its sensitivity should still be lower than phenotyping 
approach because some DPD deficiencies are also 
related to post-transcriptional changes in DPYD 
gene (mir-27,).
Somatic testing on DPYD variants on tumor tissue 
is not advocated. Although frequencies of genetic 
alterations may overlap between somatic and germ-
line testing, a somatic tumor mutation is not pre-
dictive for a germline mutation. It has previously 
been shown that tumoral DNA is not suitable to 
determine the germline CYP2D6 genotype for the 
prediction of tamoxifen responsiveness [13]. No 
dose adaptations can be suggested on the basis of 
a somatic finding only. A patient with a suggestion 
of a DPYD variant in tumor tissue will have to 
undergo subsequent germline analysis, delaying 
the start of treatment.
Implementation, technical aspects, cost and 
availability in Belgium
Genotyping is performed on whole blood (EDTA tube). 
Samples should be kept at room temperature.
(a) Targeted genotyping: ‘Short cut’ to four most 
important DPYD variants (DPYD*2A, DPYD*13, 
c.2846A>T and HapB3 of the DPYD gene). The 
cost of the test is € 160.50, € 8.68 for the patient. 
TAT around 10 days.
(b) Full DPYD sequencing: All variants. The cost of 
the test is € 369.57; € 8.68 for the patient. TAT 2 
(−4) weeks.
In order to improve TAT, it is best to send samples 
directly to the performing labs, using the correct appli-
cation form.
Labs that are currently performing targeted geno-
typing are:
● Centre de Génétique Humaine – CHU Sart-Tilman
● Centrum Menselijke Erfelijkheid – KULeuven
● Centre de Génétique Humaine – Cliniques univer-
sitaires St-Luc, UCLouvain
● Centrum Medische Genetica – UZ Gent
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Labs that also perform DPYD sequencing of all var-
iants are:
● Centre de Génétique Humaine-Cliniques universi-
taires St-Luc, UCLouvain
● Centrum Medische Genetica – UZ Gent
Phenotyping is performed using chromatography 
(HPLC-UV/HPLC diode array detection/HPLC-MS/MS) 
on blood samples with anticoagulant and without 
separating gel (10 ml heparin tube). TAT is around 
10 days maximum when the analysis is performed on 
a weekly basis.
Pre-analytical conditions are crucial:
● Delay between blood sampling and centrifuga-
tion should be <1h30 when the sample is kept 
at room temperature and <4 h at 4°C
● The sample should be centrifuged at 4°C, with 
subsequent immediate freezing of the plasma
● Plasma samples should be kept at −20°C before 
analysis (also during transportation between dif-
ferent centres)
The results of the phenotyping test are unreliable if 
these precautions have not been taken and the test 
must be repeated with a new blood sample. All labora-
tories performing the test should participate to an exter-
nal quality control program to certify the analytical phase.
BGDO recommendaon DPD-deficiency screening 
Phenotyping and Dose Adaptations: 
Different studies have set the cut-off for partial DPD deficiency as determined by uracil at 
14ng/mL ( 1,2, 9-12).  
There is less evidence suggesting a cut-off for total DPD deficiency (severe toxicity): a value 
of 100 ng/ml is currently used by experts and recommendations (2). 
- A value of uracil ≥ 100 ng/mL is considered as compatible with total DPD deficiency 
(provided preanalytical aspects have been respected) and administration of 5-FU or 
capecitabine is contra-indicated. Risk of severe toxicity due to fluoropyrimidines is 
very high. 
- A value of uracil between 14 ng/mL and < 100 ng/mL is considered as compatible 
with a partial DPD deficiency and associated with an increased risk of toxicity on 
fluoropyrimidines, so dose adaptations should be made. Often, a dose reduction of 
50% is chosen (expert recommendation).   
- A value of uracil < of = 14 ng/mL is considered as compatible with a normal DPD 
activity (12).
- Genotyping should be performed when the phenotyping test shows a value above 14 
ng/mL (up to maximum 15% of the patients), because dose adaptations are better 
validated up to now for the 4 most important variants (see CPIC recommendation). 
- Both UH2/U and uracil should be reported by the laboratory to the clinicians, because 
UH2/U ratio can give additional and potentially useful information (12). 
Figure 2. Phenotyping and dose adaptations.
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The cost of the test is € 35–40 for the patient, 
currently not reimbursed.
Labs that are currently performing phenotyping 
tests are:
● Cliniques universitaires St-Luc, UCLouvain
● CHU Sart-Tilman
● UZ Gent
● Labo Klinische Biologie, Onze-Lieve- 
Vrouwziekenhuis – Aalst
It is recommended to test for DPD deficiency before 
starting 5FU-based chemotherapy. In order not to 
delay treatment, oncologists should implement pheno-
type and/or targeted genotype testing early in the man-
agement of malignancies requiring fluoropyrimidines. In 
order not to lose time through shipment, it is necessary 
to send blood samples directly to the labs performing 
the tests. Both phenotyping and targeted genotyping 
test can be performed simultaneously, or a stepwise 
procedure can be implemented, first performing phe-
notyping because of its higher sensitivity followed by 
genotyping for uracilemia above the threshold of 14 ng/ 
mL. However, in order not to lose time with this step-
wise procedure, the flow of samples has to be secured, 
e.g. by already taking two blood samples before initia-
tion of 5-FU and sending the second sample to the 
genetic laboratory immediately when a high uracil (or 
a low UH2/U ratio) is detected.
● If we calculate 17 000 new tests per year in 
Belgium, the cost for screening all patients would 
amount up to 2.5 million euro for targeted geno-
typing. The cost of performing screening with phe-
notyping alone would be up to 680 000 euro.
● If we would use a stepwise approach, estimating 
that up to 15% of patients would have an ele-
vated uracil and require genetic testing, the cost 
would be around 1 million euro.
International guidelines and proposals
The need for an upfront genotyping or phenotyping 
strategy has been discussed in other European coun-
tries and at the European level.
Targeted genotyping of the four most important 
DPYD variants before starting fluoropyrimidine has 
been implemented in the Netherlands after the pub-
lication of the prospective safety analysis on DPYD 
genotype-guided dose individualization of fluoropyri-
midine therapy and the cost-efficiency analysis [7,8]. 
The Clinical Pharmacogenetics Implementation 
Consortium also endorses genotype-guided dose indi-
vidualization and publishes and updates guidelines [4].
France asked EMA (by PRAC) to take action at the EU 
level (3/2019) regarding the detection of the DPD defi-
cient patients and the methods that should preferably 
be used. This led to the EMA statement in April 2020, 
recommending phenotype and/or genotype testing 
for DPD deficiency prior to using 5-FU, capecitabine 
or tegafur, endorsed in the ESMO guidelines [3].
Treatment with fluorouracil, capecitabine or tega-
fur-containing medicines is contraindicated in 
patients with known complete DPD deficiency. 
A reduced starting dose should be considered in 
patients with identified partial DPD deficiency. No 
further advice on specificities of the tests or guidance 
on optimal dosing methods are given.
In Belgium, we recommend phenotype or tar-
geted genotype testing for DPD deficiency before 
starting 5-FU, capecitabine or tegafur. We strongly 
suggest a stepwise approach using phenotype test-
ing upfront because of the higher sensitivity and 
the lower cost for the society.
Conclusion:
It is recommended to perform phenotype and/or 
genotype testing for DPD deficiency prior to using 
5-FU, capecitabine or tegafur. In order not to delay 
treatment, oncologists should implement phenotype 
and/or (targeted) genotype testing early at diagnosis 
for patients in metastatic setting or patients that 
require neo-adjuvant chemotherapy and early after 
surgery in patients that need adjuvant treatment. 
Treatment with fluorouracil, capecitabine or tegafur- 
containing medicines is contraindicated in patients 
with known total DPD deficiency. A reduced starting 
dose should be considered in patients with identified 
partial DPD deficiency.
Pre-analytical conditions are critical when U and UH2/ 
U are measured. In patients with U above 14 ng/mL, we 
recommend dose adjustments and genetic testing.
Targeted genotyping can also be performed imme-
diately. In order to ensure a short TAT, EDTA blood 
samples should be sent as soon as possible to one of 
the reference laboratories. Specific and validated gen-
otype-based dose adaptations are available for hetero-
zygous or homozygous/compound heterozygous 
patients for one of the four best characterized variants, 
i.e. DPYD*2A, DPYD*13, c.2846A>T and HapB3.
For patients without total DPD deficiency, starting 
treatment with dose reductions, subsequent adjustments 
need to be discussed according to clinical tolerance 
[14–17].
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